AUPH - Aurinia partner Otsuka files marketing application for voclosporin in Europe

Aurinia Pharmaceuticals' (AUPH) licensing partner, Otsuka Pharmaceutical ((OPEL)) has filed an initial Marketing Authorization Application ((MAA)) for voclosporin for the treatment of lupus nephritis ((LN)) to the EMA.LN is a complication of the autoimmune disease systemic lupus erythematosus that impacts kidneys.In January 2021, the FDA approved voclosporin combo regimen for treatment of LN and it is currently available in U.S. under the brand name Lupkynis. In December 2020, Aurinia collaborated with OPEL for the development and commercialization of voclosporin for LN in Europe, Japan and Russia.

For further details see:

Aurinia partner Otsuka files marketing application for voclosporin in Europe